American Century Companies Inc. Has $3.41 Million Position in Medpace Holdings, Inc. $MEDP

American Century Companies Inc. lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 21.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,188 shares of the company’s stock after selling 2,979 shares during the quarter. American Century Companies Inc.’s holdings in Medpace were worth $3,409,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Northern Trust Corp raised its holdings in shares of Medpace by 13.2% during the 4th quarter. Northern Trust Corp now owns 248,142 shares of the company’s stock valued at $82,440,000 after purchasing an additional 28,968 shares in the last quarter. Jane Street Group LLC increased its position in Medpace by 3.3% during the fourth quarter. Jane Street Group LLC now owns 12,630 shares of the company’s stock worth $4,196,000 after buying an additional 406 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Medpace during the fourth quarter valued at about $14,950,000. Algert Global LLC lifted its position in shares of Medpace by 34.9% in the fourth quarter. Algert Global LLC now owns 42,157 shares of the company’s stock worth $14,006,000 after buying an additional 10,909 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of Medpace by 21.4% during the 4th quarter. Ameriprise Financial Inc. now owns 231,164 shares of the company’s stock worth $76,793,000 after acquiring an additional 40,727 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on MEDP. TD Cowen reissued a “sell” rating and issued a $366.00 price objective (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Mizuho increased their price target on Medpace from $328.00 to $510.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Truist Financial lifted their price target on shares of Medpace from $298.00 to $436.00 and gave the company a “hold” rating in a research report on Wednesday, July 23rd. William Blair reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Finally, Barclays raised their target price on shares of Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $406.60.

Insiders Place Their Bets

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $2,725,380. This trade represents a 66.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.14, for a total value of $3,376,050.00. Following the sale, the vice president directly owned 57,500 shares in the company, valued at $25,883,050. The trade was a 11.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 115,070 shares of company stock valued at $52,085,751 in the last quarter. 20.30% of the stock is currently owned by insiders.

Medpace Trading Up 0.5%

MEDP opened at $475.51 on Friday. The business has a 50 day moving average of $395.75 and a 200-day moving average of $339.38. The stock has a market capitalization of $13.36 billion, a price-to-earnings ratio of 35.35, a P/E/G ratio of 2.99 and a beta of 1.42. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $501.30.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to analysts’ expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.